Skip to main content

Table 2 Comparison of evaluation indices after treatment (drug or placebo) in patients with BPH and nocturia

From: The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study

Variable

Drug reatment

Placebo Treatment

P value

Number of patients

80

68

 

Age (years)

69.5 ± 5.6

68.5 ± 5.3

0.450

I-PSS

16.8 ± 4.9

19.3 ± 5.0

0.002

Storage symptom score

10.3 ± 3.4

10.7 ± 3.4

0.007

Voiding symptom score

6.5 ± 2.4

8.6 ± 2.3

0.003

QoL score

3.1 ± 0.6

3.8 ± 1.0

0.005

Serum PSA (ng/ml)

2.2 ± 1.7

2.1 ± 1.6

0.355

Prostate volume (ml)

39.4 ± 19.4

41.4 ± 20.1

0.235

Qmax

14.0 ± 2.4

16.5 ± 2.6

0.043

24-h drinking volume (ml)

1465.4 ± 624.8

1505.4 ± 610.8

0.356

4-h before bedtime drinking volume (ml)

115.8 ± 100.9

106.6 ± 97.9

0.452

Frequency of nocturia

2.8 ± 0.7

3.0 ± 0.6

0.306

Frequency of daytime urination

7.5 ± 2.6

8.1 ± 2.6

0.002

Maximum urination volume (ml)

372.8 ± 103.3

302.8 ± 119.3

0.007

Morning urine volume (ml)

280.5 ± 111.7

259.5 ± 100.7

0.003

24-h total urine volume (ml)

1965.5 ± 623.5

1896.5 ± 637.5

0.231

Nocturnal urine volume (ml)

800.7 ± 323.0

845.7 ± 303.5

0.056

  1. LUTS lower urinary symptom, PSA prostate-specific antigen